First-line regimens now include novel drugs such as BTK inhibitors (ibrutinib), newer anti-CD20 monoclonal antibodies (obinituzumab), or BCL-2 inhibitors (venetoclax).12 Therefore, comparatively speaking, our five patients who had the newer regimens did not actually receive novel therapy, and this may explain the poor survival in our patients with CLL compared with other climes. Here, BCL2 is linked to B-cell chronic lymphocytic leukemia.